Aim:
To estimate reattendance rates in men with symptoms of urethritis if POC testing for CT and GC is introduced, using a decision tree care pathway model Methods:
All men with urethritis symptoms presenting to BSHC over a three month period were identified using electronic patient records (EPR). Reattendances within 30 days of initial clinic visit and reasons for reattendance were recorded via interrogation of the EPR and a decision tree care pathway model constructed (left side of figure) . This pathway was then modified assuming all men have a CT/GC POC test >1.5 hours prior to being seen by the clinician and the result was available prior to clinical examination (right side of figure) . GC-positive urethritis is treated as before and assumed to 100% effective. A test of cure is undertaken by asking the patient to drop off a specimen for POC testing which does not require clinic re-registration. CT-positive NGU is treated with doxycycline 100mgs bd 7/7 and assumed to be 95% effective and CT-negative urethritis with the extended azithromycin regimen which is assumed to be 90% effective. If men with NGU re-attend and are diagnosed with persistent urethritis an extended azithromycin regimen is then used if they had been treated with doxycycline, and Moxifloxacin 400mgs od 14 days is used if they had been treated initially with the extended azithromycin regimen. In both situations metronidazole 400mgs bd 5 days is also administered. The cure rate is assumed to be 95%. MG prevalence is assumed to be 20% with <5% macrolide anti-microbial resistance.
The model was then propagated with a hypothetical population of 400 men using the EPR prevalence and probability estimates and the assumptions detailed above.
Results
431 men with urethritis symptoms were identified in a 3 month period. Of these 385 had a urethral smear and 192 (50% [95% CI, 45-55%]) had confirmed urethritis on initial microscopy. 9 (19% [95% CI, 10-32%]) of 48 men with chlamydia urethritis re-attended of whom 3 did so because of unprotected sexual intercourse with an untreated partner and 31(29% [95% CI, 21-38%] ) of 106 men with chlamydia-negative NGU re-attended at least once within 30 days of initial visit. 46(12% [95% CI, 9.1-16%]) men with a negative urethral smear re-attended with persistent symptoms and 17(4.4% [95% CI, 4.4-7%]) had urethritis on repeat microscopy. In addition of these men 5(1%) were GC-positive and 8(2%) CT-positive.
It was estimated by comparing care pathways that POC testing could reduce microscopy by 25% and repeat reattendance following treatment by 75% through improved pathogen-directed treatment and the introduction of GC POC testing sample drop-off as a test of cure.
Conclusions:
This service evaluation identified high reattendance rates in men with symptoms of urethritis CT/NG POC testing has the potential to substantially reduce reattendance rates. This would require the CT/GC POC test result to be available prior to the clinical examination. Figure: Care pathway maps comparing current management with hypothetical care pathway if POC testing was introduced
